Bryan Moyer
Senior Vice President, Discovery Latigo Biotherapeutics
Bryan is the co-founder of Latigo Biotherapeutics and currently serves as senior vice president of discovery. Bryan has more than 25 years of experience in research and development, with an established record leading drug discovery teams for target identification, target engagement in translatable models of human disease and clinical candidate delivery.
Prior to Latigo, and during his 10-year tenure at Amgen, he led multi-modality discovery programs to advance small molecule, peptide, and antibody-based therapeutics for pain and migraine indications.
Bryan developed and launched a multi-species discovery effort to identify new pain target genes using genomics, bioinformatics, and genetics approaches. Prior to Amgen, Bryan was at Senomyx, a biotechnology company working on taste biology, where he led drug discovery and target identification efforts for taste receptors and transmembrane targets.
Bryan has a B.S. in Animal Physiology and Neuroscience from the University of California, San Diego, a Ph.D. in Physiology from Dartmouth Medical School, and completed his postdoctoral fellowship at The Scripps Research Institute in La Jolla, California.
Seminars
- Present compound potency, selectivity and mechanism of action
- Discuss translatable models of Nav1.8 target engagement
- Highlight efficacy in model systems: human DRG neurons and NHP microneurography
- Correlate inhibition of action potential firing with target inhibition levels
- Following the first approval of a NaV1.8 inhibitor, where do the greatest opportunities for differentiation lie across NaV1.8, NaV1.7, NaV1.9 and other emerging sodium channel targets in acute, chronic and neuropathic pain?
- How should developers balance efficacy, safety, tolerability, tissue selectivity, CNS penetration and dosing convenience when designing next-generation sodium channel therapies?
- Is meaningful improvement now more likely to come through better molecule design, target engagement and patient selection, or through targeting different sodium channel subtypes and pain mechanisms?
- Which pain populations are most likely to benefit from specific sodium channel approaches, and how can developers better match mechanism to underlying disease biology and pain phenotype?
